Catherine M. Burzik - 05 Aug 2022 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Reporting relationship: Director
Issuer ticker: HAE
Reported as of: 05 Aug 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Aug 2022, 17:20:22 UTC
Prior SEC filing: 08 Jun 2022
Next SEC filing: 09 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Thomas V. Powers, attorney-in-fact for Ms. Burzik

Key filing fact

Catherine M. Burzik filed Form 4 for HAEMONETICS CORP (HAE) on 08 Aug 2022.

Key facts

This page summarizes Catherine M. Burzik's Form 4 filing for HAEMONETICS CORP (HAE).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 08 Aug 2022, 17:20.

Change

Previous filing in this sequence was filed on 08 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HAE transaction

Common Stock

Award

Transaction value
Shares: +2,730
Change %: +16%
Price
Shares after: 19,545
Date: 05 Aug 2022
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

Footnote F2

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.